GH Optimization Research Stack

£59.99

Purity: ≥ 99%

£59.99

GH Optimization Research Stack

Name: GH Optimization Research Stack
Brand: Pure Grade Labs
Price: 59.99 GBP
Availability: OutOfStock

£59.99

Purity: ≥ 99%

£59.99

GH SECRETION - Growth hormone pulse release and secretion research

RECEPTOR SELECTIVITY - Targeted GH receptor binding and activation research

IGF-1 MODULATION - Downstream growth factor and muscle signalling research

PHARMACOKINETICS - Extended half-life & sustained release mechanism research

Two Compounds. Two Receptors. One Protocol.

The GH Optimisation Stack combines CJC-1295 with DAC and Ipamorelin - two structurally distinct growth hormone secretagogues that operate through independent receptor pathways. CJC-1295 + DAC is a GHRH analogue that binds to the pituitary GHRH receptor. Ipamorelin is a ghrelin receptor agonist (GHS-R1a) that triggers GH release through a separate, non-overlapping mechanism.

The rationale for studying these compounds together is mechanistic rather than additive. Research on combined GHRH and GHS administration - the class to which CJC-1295 and Ipamorelin respectively belong - has consistently demonstrated GH secretion that exceeds what either class produces independently, due to their complementary receptor engagement and distinct intracellular signalling cascades. This stack is designed for researchers investigating dual-pathway GH axis modulation.

CJC-1295 + DAC

A modified GHRH analogue with Drug Affinity Complex (DAC) technology. The DAC modification binds the peptide to serum albumin, extending half-life from approximately 30 minutes (unmodified) to 6-8 days. Studied for sustained GHRH receptor engagement and pulse amplitude augmentation in GH secretion research.

Ipamorelin

A pentapeptide GH secretagogue with selective GHS-R1a agonism. Distinguished from earlier secretagogues (GHRP-2, GHRP-6) by its selectivity profile: Raun et al. (1998) identified Ipamorelin as the first GH secretagogue studied without significant cortisol or prolactin co-stimulation, making it the preferred compound in selective GH axis research protocols.

CJC-1295 + DAC Sequence (Modified): Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Lys-OH [+ DAC]

Ipamorelin Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2

CJC-1295 DAC MW: ~4,815 g/mol

Ipamorelin MW: 711.9 g/mol

CJC-1295 DAC CAS: 863288-34-0

Ipamorelin CAS: 170851-70-4

2006 | Journal of Clinical Endocrinology & Metabolism | Phase I/II Human Trial

CJC-1295 increases GH and IGF-1 levels in healthy adults with extended duration of action

Ionescu & Frohman conducted a randomised, double-blind, placebo-controlled study of CJC-1295 in 65 healthy adult subjects aged 21-61. Single subcutaneous doses of CJC-1295 produced dose-dependent increases in mean plasma GH concentrations by 2-10 fold above baseline, with effects sustained for 6 days post-administration. IGF-1 levels increased by 1.5-3 fold and remained elevated for 9-11 days. The authors concluded that CJC-1295 produces "physiological" GH responses characterised by pulsatility rather than supraphysiological spikes, distinguishing it from exogenous HGH administration. No serious adverse events were reported across dose groups.

Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed →

1998 | European Journal of Endocrinology | Animal / In Vitro

Ipamorelin: the first selective growth hormone secretagogue

Raun et al. characterised Ipamorelin in a landmark study that established its selectivity profile relative to other GH secretagogues. In rat models, Ipamorelin produced robust, dose-dependent GH release comparable to GHRP-6, but crucially without the cortisol, ACTH, or prolactin co-stimulation observed with GHRP-6 and hexarelin at equivalent doses. The authors documented that this selectivity was specific to the GHS-R1a receptor, with minimal off-target receptor activity detected in binding assays. The study established Ipamorelin as the reference selectivity standard for GH secretagogue research and the compound has been used in subsequent mechanistic studies specifically because of this clean receptor profile.

Raun K, et al. Eur J Endocrinol. 1998;139(5):552-561. PubMed →

1994 | Journal of Clinical Endocrinology & Metabolism | Human Clinical Study

Combined GHRH and GHS administration produces synergistic GH release exceeding either compound alone

Bowers et al. investigated the interaction between GHRH receptor agonism and GH secretagogue (GHS) administration across in vitro, animal, and human study arms. The study documented that combined GHRH + GHS administration produced GH secretion that was substantially greater than additive - defined by the authors as "synergistic" - with human subjects showing GH pulse amplitudes 6-7x above baseline under combined administration versus 2-3x for GHRH alone. The effect was attributed to dual-pathway co-activation: the Gs/cAMP cascade (GHRH receptor) and the Gq/IP3/Ca2+ cascade (GHS-R1a) converging at the exocytosis level. This study provided the foundational mechanistic rationale for dual-compound GH axis research protocols that remains the basis for combination studies today.

Bowers CY, et al. J Clin Endocrinol Metab. 1994;79(4):940-946. PubMed →

2005 | Endocrinology | Animal Study

DAC technology confers extended half-life and sustained biological activity on GHRH analogues

Jetté et al. studied the pharmacokinetic and pharmacodynamic properties of DAC-modified GHRH analogues, characterising the albumin-binding mechanism responsible for the extended half-life of CJC-1295. The study demonstrated that the maleimide-based DAC moiety forms a covalent bond with cysteine-34 of albumin in vivo, achieving a half-life of approximately 19 days in rodents and producing sustained GH and IGF-1 elevation that outlasted unmodified GHRH analogues by a factor of greater than 50. The research validated the DAC approach as a method to convert short-acting GHRH peptides into long-duration receptor agonists suitable for extended research protocols.

Jetté L, et al. Endocrinology. 2005;146(7):3052-3058. PubMed →

Every GH Optimisation Stack ships with a batch-specific Certificate of Analysis from an independent third-party analytical laboratory. The COA covers both vials in the stack and confirms identity, purity by HPLC, and absence of contaminants. Batch-specific documentation is linked below.

Both compounds are supplied as lyophilised (freeze-dried) solids. Correct handling preserves compound integrity. Storage and reconstitution specifications below apply to both CJC-1295 + DAC and Ipamorelin vials unless otherwise noted.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow sealed vials to reach room temperature before opening to minimise moisture introduction.
Use bacteriostatic water (BAC water) as reconstitution solvent. Available separately (PGL-BAC-10). Add solvent slowly down the inside wall of the vial - do not inject directly onto the lyophilised cake.
Gently swirl each vial until fully dissolved. Do not vortex or shake vigorously.
Once reconstituted, store at 2-8°C. Use within 28 days. Do not freeze reconstituted solution.
Discard if solution appears cloudy, discoloured, or contains particulate matter.

CJC-1295 + DAC and Ipamorelin supplied by Pure Grade Labs are intended exclusively for in vitro research and laboratory use. These products are not approved for human or veterinary use by any regulatory authority, including the FDA, MHRA, TGA, or EMA.

These products are not drugs, medicines, or supplements and must not be used as such.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy in humans.
These products must not be administered to humans or animals outside of a licensed research context.
Both CJC-1295 and Ipamorelin are prohibited in sport by WADA under the S2 Peptide Hormones category. Athletes subject to drug testing should be aware of this classification.
Purchasers are solely responsible for compliance with all applicable laws and regulations in their jurisdiction.

All research summaries and study citations on this page are provided for informational context only and do not constitute medical advice, endorsement of any treatment, or recommendation for human use.